Angiotensin converting enzyme-inhibitor reduces colitis severity in an il-10 knockout model

Digestive Diseases and Sciences

Volumn 58, Issue 11, 2013, Pages 3165-3177

  Sueyoshi, Ryo ^a   Ignatoski, Kathleen M Woods ^a   Daignault, Stephanie ^b   Okawada, Manabu ^a   Teitelbaum, Daniel H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Angiotensin; Colitis; IL 10 deficient; Renin angiotensin system; Steroid

Indexed keywords

CYTOKINE; ENALAPRILAT; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INTERLEUKIN 10; PIROXICAM; PLACEBO; PREDNISOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; COLITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; COLITIS; DEXTRAN SULFATE; ENALAPRILAT; INTERLEUKIN-10; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84889579156     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2825-4     Document Type: Article

References (51)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
3. Duggan KA, Mendelsohn FA, Levens NR. Angiotensin receptors and angiotensin I-converting enzyme in rat intestine. Am J Physiol. 1989;257:G504-G510.
4. Jaszewski R, Tolia V, Ehrinpreis M, et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology. 1990;98:1543-1548.
5. Wildhaber B, Yang H, Haxhija E, et al. Intestinal intraepithelial lymphocyte derived angiotensin converting enzyme modulates epithelial cell apoptosis. Apoptosis. 2005;10:1305-1315.
6. Spencer A, Yang H, Haxhija E, et al. Reduced severity of a mouse colitis model with angiotensin converting enzyme inhibition. Dig Dis Sci. 2007;52:1060-1070.
7. Inokuchi Y, Morohashi T, Kawana I, et al. Amelioration of 2, 4, 6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut. 2005;54:349-356.
8. Wengrower D, Zannineli G, Pappo O, et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF-beta1. Inflamm Bowel Dis. 2004;10:536-545.
9. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation 1. Annu Rev Immunol. 2002;20:495-549.
10. Laroui H, Ingersoll SA, Liu HC, et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS ONE. 2012;7:e32084.
11. Kühn R, Löhler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
12. Hale LP, Gottfried MR, Swidsinski A. Piroxicam treatment of IL-10-deficient mice enhances colonic epithelial apoptosis and mucosal exposure to intestinal bacteria. Inflamm Bowel Dis. 2005;11:1060-1069.
13. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010-1020.
14. Davidson NJ, Hudak SA, Lesley RE, et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol. 1998;161:3143-3149.
15. Berg DJ, Zhang J, Weinstock JV, et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology. 2002;123:1527-1542.
16. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukoc Biol. 1997;61:389-396.
17. Haxhija E, Yang H, Spencer A, et al. Modulation of mouse intestinal epithelial cell turnover in the absence of angiotensin converting enzyme. Amer J Physiol Gastroint Liver Physiol. 2008;295:G88-G98.
18. Cooper HS. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238-249.
19. Saverymuttu SH. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology. 1986;90:1121-1128.
20. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580-591.
21. Lennernäs H, Nylander S, Ungell AL. Jejunal permeability: a comparison between the using chamber technique and the single-pass perfusion in humans. Pharm Res. 1997;14:667-671.
22. Yang H, Finaly R, Teitelbaum DH. Alteration in epithelial permeability and ion transport in a mouse model of total parenteral nutrition. Crit Care Med. 2003;31:1118-1125.
23. Krug SM, Amasheh S, Richter JF, et al. Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability. Mol Biol Cell. 2009;20:3713-3724.
24. Feng Y, Sun X, Yang H, Teitelbaum D. Dissociation of E-cadherin and beta-catenin in a mouse model of total parenteral nutrition: a mechanism for the loss of epithelial cell proliferation and villus atrophy. J Physiol (London). 2009;587:641-654.
25. Ahlin P, Kristl J, Kristl A, et al. Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm. 2002;239:113-120.
26. Okawada M, Koga H, Larsen S, et al. Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Dig Dis Sci. 2011;56:2553-2565.
27. Liu Z, Zhang P, Ma Y, et al. Lactobacillus plantarum prevents the development of colitis in IL-10-deficient mouse by reducing the intestinal permeability. Mol Biol Rep. 2011;38:1353-1361.
28. Clayburgh DR, Barrett TA, Tang Y, et al. Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest. 2005;115:2702-2715.
29. Manz M, Vavricka SR, Wanner R, et al. Therapy of steroid-resistant inflammatory bowel disease. Digestion. 2012;1:11-15.
30. Wildhaber B, Yang H, Coran A, Teitelbaum D. Gene alteration of intestinal intraepithelial lymphocytes in response to massive small bowel resection. Pediatr Surg Int. 2003;19:310-315.
31. Papp M, Li X, Zhuang J, et al. Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol. 2002;282:L713-L718.
32. Uhal BD, Gidea C, Bargout R, et al. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol. 1998;275:L1013-L1017.
33. Haxhija EQ, Yang H, Spencer AU, et al. Modulation of mouse intestinal epithelial cell turnover in the absence of angiotensin converting enzyme. Am J Physiol Gastroint Liver Physiol. 2008;295:G88-G98.
34. Koga H, Yang H, Adler J, et al. Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment. Surgery. 2008;144:259-268.
35. Mizushima T, Sasaki M, Ando T, et al. Blockage of angiotensin II type 1 receptor regulates TNF-α-induced MAdCAM-1 expression via inhibition of NF-κB translocation to the nucleus and ameliorates colitis. Am J Physiol Gastroint Liver Physiol. 2010;298:G255-G266.
36. Koga H, Haxhija EQ, Teitelbaum DH. The role of angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model. Pediatr Surg Int. 2008;24:1279-1286.
37. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477-481.
38. Imai Y, Kuba K, Penninger JM. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol. 2008;93:543-548.
39. Ikenoue Y, Tagami T, Murata M. Development and validation of a novel IL-10 deficient cell transfer model for colitis. Int Immunopharmacol. 2005;5:993-1006.
40. Pang T, Benicky J, Wang J, et al. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-gamma activation in human monocytes. J Hypertens. 2012;30:87-96.
41. Okada Y, Maeda N, Takakura S, et al. Preventive and therapeutic effects of tacrolimus in an interleukin-10-deficient mouse model of colitis. Inflamm Res. 2011;60:1049-1059.
42. Fiorentino D, Zlotnik A, Mosmann T, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol. 1991;147:3815-3822.
43. Ito K, Takaishi H, Jin Y, et al. Staphylococcal enterotoxin B stimulates expansion of autoreactive T cells that induce apoptosis in intestinal epithelial cells: regulation of autoreactive responses by IL-10. J Immunol. 2000;164:2994-3001.
44. Nemati F, Rahbar-Roshandel N, Hosseini F, et al. Anti-Inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension. Clin Exp Hypertens. 2011;33:66-76.
45. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs. 2002;3:569-577.
46. Miguel-Carrasco J, Zambrano S, Blanca A, et al. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm. 2010;7:21.
47. Nishiyori A, Nagakura Y, Ichikawa K. Piroxicam accelerates development of colitis in T-cell receptor α chain-deficient mice. Eur J Pharmacol. 2009;615:241-245.
48. Okuda T, Yoshida N, Takagi T, et al. CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis. Dig Dis Sci. 2008;53:657-663.
49. Makins R. Gastrointestinal side effects of drugs. Expert Opin Drug Saf. 2003;2:421-429.
50. Schmidt TD, McGrath KM. Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am J Med Sci. 2002;324:106-108.
51. Higgins PDR, Davis KJ, Laine L. The epidemiology of ischaemic colitis. Aliment Pharmacol Ther. 2004;19:729-738.